typical dosage cjc 1295 ipamorelin cjc-1295 blend mcg cjc-1295 ipamorelin blend typical dosage CJC-1295/Ipamorelin Dosage Protocol: The Complete Clinical Guide to CJC 1295 & Ipamorelin Benefits,

Fat deposits decreased by 39% on average

Anastomosis without leakage induces markedly higher volume and pressure values, with a continuous increase toward healthy values

Gao B, Bataller R

Full disclaimer 1.AOD-9604 is a 16-amino acid peptide fragment derived from human growth hormone (hGH residues 177-191) with added tyrosine, developed by Metabolic Pharmaceuticals for obesity treatment 2.Proposed mechanism: selective stimulation of lipolysis (fat breakdown) and inhibition of lipogenesis (fat formation) without growth hormone-like effects on IGF-1 or blood glucose 3.Failed Phase 2b clinical trial for obesity (2007)did not demonstrate statistically significant weight loss versus placebo, terminating clinical development for this indication 4.Received FDA "Generally Recognized as Safe" (GRAS) designation in 2023 as a food substance, but this is NOT a drug approval and does not establish efficacy for weight loss 5.Regulatory status: not FDA-approved as a drug, prohibited by WADA, and insufficient evidence for weight loss efficacy

TB-500 safety data is less extensive but similarly suggests good tolerability in preclinical models